The melanogenesis and mechanisms of skin-lightening agents--existing and new approaches.
Skin-lightening products are commercially available for cosmetic purposes to obtain lighter skin complexion. Clinically, they are also used for treatment of hyperpigmentary disorders such as melasma, café au lait spot and solar lentigo. All of these target naturally melanin production, and many of the commonly used agents are known as competitive inhibitors of tyrosinase, one of the key enzymes in melanogenesis. In this review, we present an overview of commonly used skin-whitening ingredients that are commercialized, but we also hypothesize on other mechanisms that could be important targets to control skin pigmentation such as for example regulation of the adrenergic and glutaminergic signalling and also control of tetrahydrobiopterins in the human skin.
Oriflame Cosmetics Skin Research Institute, SE-101 39 Stockholm, Sweden.
J M
JM
Gillbro
M J
MJ
Olsson
D003879:Dermatologic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D017495:Hyperpigmentation / Q000188:drug therapy*; D008543:Melanins / Q000096:biosynthesis*; D020460:Melanosomes / Q000187:drug effects / Q000378:metabolism; D014442:Monophenol Monooxygenase / Q000037:antagonists & inhibitors / Q000378:metabolism; D012880:Skin Pigmentation / Q000187:drug effects / Q000502:physiology*
D003879:Dermatologic Agents; D004791:Enzyme Inhibitors; D008543:Melanins; D014442:Monophenol Monooxygenase